Location Directory

Clinical trials in Chicago, Illinois

This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

4127

Shown on this page

Current sort

Institutions in Chicago

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Stored official records

Open in full search

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Docetaxel, Pegylated G-CSF, Placebo, Selumetinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 17
States / cities: Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more

Conditions: Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Interventions: Placebo (placebo inhalation spray), treprostinil SMI (treprostinil inhalation spray); Combination Product
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more

Conditions: Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Interventions: treprostinil SMI (treprostinil inhalation spray); Combination Product
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2034
U.S. locations: 15
States / cities: Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 11 more

Conditions: Proliferative Sickle Cell Retinopathy
Interventions: Faricimab Injection for stage 3 or stage 4 Proliferative sickle cell eyes, Laser photocoagulation, Vitrectomy; Drug · Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Interventions: Roflumilast Cream 0.3%, Vehicle Cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Birmingham, Alabama • Bryant, Arkansas • Miami Lakes, Florida + 1 more

Conditions: Hypertension
Interventions: Aerobic training (AT), Core intervention (Fitbit tracking and BP health education), Dynamic resistance training (DRT), Isometric resistance training (IRT); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 44 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Inguinal Hernia
Interventions: Polydioxanone suture (PDS), Polypropylene suture (Prolene); Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Umbilical Hernia, Ventral Hernia
Interventions: Duramesh, Mesh; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Stage IIIa, Liver Cancer Stage IIIb, Liver Cancer Stage IIIc, Liver Cancer Stage IV, Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
Interventions: EUS-Guided MWA Device; Device
Lead sponsor: Banner Health; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Gilbert, Arizona • Los Angeles, California • Chicago, Illinois + 3 more

Conditions: Rheumatoid Arthritis
Interventions: PTC844, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Chandler, Arizona • Flagstaff, Arizona • Phoenix, Arizona + 10 more

Conditions: Alzheimer's Disease
Interventions: Placebo, Trontinemab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 24
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 20 more

Conditions: Overweight or Obesity
Interventions: Olatorepatide, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Mobile, Alabama • Walnut Creek, California • Waterbury, Connecticut + 17 more

Clinical trials in Chicago, Illinois

Filter and sort this location

Institutions in Chicago

Stored official records

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS)

Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis

A MOST Framework Trial Evaluating the MOst effectiVe Exercise Types for Blood Pressure Control

Permanent Versus Slowly Dissolving Stitches for Non-Mesh (Shouldice) Groin Hernia Repair

Duramesh Versus Minimally Invasive IPOM for High-Risk Umbilical Hernia Repairs

CREO - Microwave Ablation Feasibility Study

Study of PTC844 in Participants With Active Rheumatoid Arthritis

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes